The Inflation Reduction Act includes drug price negotiation as a key component. Whether drugs were selected for negotiation in 2023 or will be chosen in the future, their impact will be significant, especially in therapeutic areas affected by negotiation. Manufacturers are proactively assessing risk and preparing for the margin impact resulting from negotiation.

Key Takeaways

• Learning about a strategic approach to anticipating price negotiation
• Lessons from the first round of selection and negotiation
• Insights into the possible evolution of drug price negotiation

 

Speakers:

James Brown
Vice President, U.S. Market Access Strategy Consulting, IQVIA

Rob Glik
Vice President and GM, Value & Access Strategy Consulting, IQVIA